Finoriq research workspace

aTYR PHARMA INC (ATYR) Historical Metrics

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development. Review ATYR fundamentals, ratios, and historical filing metrics on Finoriq.

Company Snapshot

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Company

aTYR PHARMA INC (ATYR)

Ticker

ATYR

Market Cap

$47.8M

Latest Price

$0.488

Industry

Biotech & Pharma

Open insider transactions

aTYR PHARMA INC (ATYR) Current Valuation Metrics

Static valuation preview for aTYR PHARMA INC (ATYR). Market data retrieved 2026-07-09. Filing currency USD.

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.